RT Journal Article
SR Electronic
T1 Efficacy and longevity of immune response to 3<sup>rd</sup> COVID-19 vaccine and effectiveness of a 4<sup>th</sup> dose in severely immunocompromised patients with cancer
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.07.05.22277281
DO 10.1101/2022.07.05.22277281
A1 Astha Thakkar
A1 Kith Pradhan
A1 Benjamin Duva
A1 Juan Manuel Carreño
A1 Srabani Sahu
A1 Victor Thiruthuvanathan
A1 Sean Campbell
A1 Sonia Gallego
A1 Tushar D Bhagat
A1 Johanna Rivera
A1 Gaurav Choudhary
A1 Raul Olea
A1 Maite Sabalza
A1 Lauren C. Shapiro
A1 Matthew Lee
A1 Ryann Quinn
A1 Ioannis Mantzaris
A1 Edward Chu
A1 Britta Will
A1 Liise-anne Pirofski
A1 Florian Krammer
A1 Amit Verma
A1 Balazs Halmos
YR 2022
UL http://medrxiv.org/content/early/2022/07/06/2022.07.05.22277281.abstract
AB Cancer patients show increased morbidity with COVID-19 and need effective immunization strategies. We demonstrate that a 3rd dose of COVID-19 vaccine leads to seroconversion in 57% of patients that were seronegative after primary vaccination. The immune response is durable as assessed by anti-S antibody titers, T-cell activity and neutralization activity against wild-type SARS-CoV2 and BA1.1.529 at 6 months of follow up. A subset of severely immunocompromised hematologic malignancy patients were unable to mount adequate immune response after the 3rd dose and were treated with a 4th dose in a prospective clinical trial which led to adequate immune-boost in 67% of patients. Low baseline IgM levels and CD19 counts were associated with inadequate seroconversion. Booster doses induced limited neutralization activity against the Omicron variant. These results indicate that vaccine booster-induced immunity is durable in cancer patients and additional doses can further stimulate immunity in a subset of hematologic malignancy patients.Statement of significance We demonstrate that a 3rd dose of vaccine leads to seroconversion in 57% of negative patients with durable immune responses at 6 months. A 4th dose of vaccine can seroconvert hematologic malignancy patients with higher baseline IgM and CD19 levels.Competing Interest StatementThe Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which list Florian Krammer as co-inventor. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2. Florian Krammer has consulted for Merck and Pfizer (before 2020), and is currently consulting for Pfizer, Seqirus, 3rd Rock Ventures and Avimex. The Krammer laboratory is also collaborating with Pfizer on animal models of SARS-CoV-2.Clinical TrialNCT05016622Funding StatementThis study was supported with funding from the National Cancer Institute Grant 3P30CA013330-49S3 and NCORP Grant 2UG1CA189859-06. The authors also acknowledge support from the Jane and Myles Dempsey Family. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Work in the Krammer laboratory was partially funded by the Centers of Excellence for Influenza Research and Surveillance (CEIRS, contract # HHSN272201400008C), the Centers of Excellence for Influenza Research and Response (CEIRR, contract # 75N93021C00014), by the Collaborative Influenza Vaccine Innovation Centers (CIVICs contract # 75N93019C00051) and by institutional funds. Finally, this effort was also supported by the Serological Sciences Network (SeroNet) in part with Federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. 75N91019D00024, Task Order No. 75N91020F00003. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the U.S. Government.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by Montefiore-Einstein Institutional Review Board, IRB#2021-13204I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the corresponding author